pancreatic ductal adenocarcinoma (PDAC) tagged posts

A Powerful New Tool in the Fight Against one of the Deadliest Cancers

20231016_2_fig_2.jpg
Theranostics targeting glypican-1 (GPC1): (Left) PET imaging of Zr-89 labeled GPC1 antibody using pancreatic cancer model mouse (red arrow indicates tumor), (Right) Alpha radiation therapy using At-211-labeled anti-GPC1 antibody in a pancreatic cancer model.
Credit: Tadashi Watabe (Osaka University)

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide, with a 5-year survival rate of less than 10%. Many PDAC tumors in early stage go undetected because they are not found using conventional imaging methods, including fluorodeoxyglucose positron emission tomography (PET) scans...

Read More

Biomarker could help to Diagnose Pancreatic Cancer

Studies have identified biomarkers that may be useful in diagnosing  pancreatic cancer - Florida News Times

Researchers from Queen Mary University of London have identified a protein that could be used to aid in the diagnosis of pancreatic cancer.

Findings from the new study suggest that a protein called pentraxin 3 (PTX3) may be a specific diagnostic biomarker — or biological measure — for pancreatic cancer, with the ability to differentiate pancreatic cancer from other non-cancerous conditions of the pancreas.

The research was published today in npj Precision Oncology, and primarily funded by the Pancreatic Cancer Research Fund, Barts Charity and Cancer Research UK.

PTX3 levels elevated in patients with pancreatic cancer

In the study, researchers measured PTX3 levels in serum blood samples from patients with pancreatic ductal adenocarcinoma (PDAC) — the most common type of pan...

Read More